GSK3β is a critical therapeutic target in canonical Wnt/β-catenin and PI3K/Akt signaling pathway, and several known GSK3β inhibitors also take part in over activated Hh signaling in PDA (Pandey and DeGrado, 2016). The gene discussed is AKT1; the disease is Patent ductus arteriosus.